Last update June 22, 2022

μιφεπριστόνη

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Antiprogestin which derives from Norethisterone, Mifepristone is a cortisol receptor blocker used to treat Cushing's syndrome and to terminate pregnancies up to 50-70 days' gestation.

Its high plasma protein-binding capacity and large volume of distribution (Sarkar 2002)  explains that excretion into breast milk is clinically non-significant. It achieves very low levels in breast milk at a maternal dose of 600 mg or undetectable at maternal dose of 200 mg. (Sääv 2010)

The punctual use of mifepristone does not contraindicate breastfeeding. (LactMed, Bettahar 2016)

When used with semi-experimental purposes due to its anti-androgenic and antiglucocorticoid properties a continuous administration and / or large doses is required. There is no experience in connection with breastfeeding. Those pathologies in which it is often used on a continuous basis by themselves are not compatible with breastfeeding.

Alternatives

We do not have alternatives for μιφεπριστόνη.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

μιφεπριστόνη is Mifepristone in Greek.

Is written in other languages:

Group

μιφεπριστόνη belongs to this group or family:

Tradenames

Main tradenames from several countries containing μιφεπριστόνη in its composition:

List of 15 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 69 %
Molecular weight 430 daltons
Protein Binding 98 %
VD 1.5 l/Kg
pKa 12.87 -
Tmax 1.5 hours
T½ 18 hours
M/P ratio 0.01 - 0.04 -
Theoretical Dose < 0.026 mg/Kg/d
Relative Dose < 0.5 %

References

  1. AEMPS. Mifepristona. Ficha técnica. 2015 Full text (in our servers)
  2. Sääv I, Fiala C, Hämäläinen JM, Heikinheimo O, Gemzell-Danielsson K. Medical abortion in lactating women--low levels of mifepristone in breast milk. Acta Obstet Gynecol Scand. 2010 Abstract Full text (link to original source) Full text (in our servers)
  3. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006 Abstract
  4. FDA. Mifepristone. Drug Summary. 2004 Full text (in our servers)
  5. Baird DT. Antigestogens. Br Med Bull. 1993 Abstract

Total visits

2,203

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM